Suplatast tosilate capsules 100 mg (asthma, atopic dermatitis, allergic rhinitis)
Product Code :
Availability : 12
General information on Japanese Suplatast tosilate capsules 100 mg (asthma, atopic dermatitis, allergic rhinitis)
Package details: 100 capsules
Manufacturer: Towa Pharmaceutical Co. Ltd., Japan
Active ingredient: suplatast tosilate (chemical formula C23H33NO7S2)
Medical effect: Suplatast tosilate capsules are effective for the treatment of the following diseases and conditions:
- bronchial asthma, including atopic bronchial asthma,
- atopic dermatitis,
- allergic rhinitis,
- hyperimmunoglobulinemia E,
- Kimura’s disease.
Contraindications and precautions: do not use in pregnant or breastfeeding women. Do not use for patients with liver damage.
If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Suplatast tosilate capsules 100 mg (asthma, atopic dermatitis, allergic rhinitis)
For adults, take 1 capsule 3 times a day after meals.
The dosage may be adjusted by the consulting doctor according to age, body weight and symptoms.
How effective are Suplatast tosilate capsules 100 mg from Japan (asthma, atopic dermatitis, allergic rhinitis)?
Suplatast tosilate is a new anti-allergic drug capable of down-regulating the functions of lymphocytes. It works by inhibiting Th2 cytokine. Suplatast tosilate capsules inhibit the infiltration of lymphocytes including CD4+ T cells into healthy tissues, like lungs or broncho-bronchiolar walls. While this medicine does not affect the positivity for specific IgE antibodies against allergens, it effectively lowers the titer of the IgE antibody through specific inhibition of the production of interleukin by T cells. By this, suplatast tosilate prevents the expression of the allergic reaction.
Who should use Suplatast tosilate capsules 100 mg from Japan?
Japanese Suplatast tosilate capsules are effective against bronchial asthma, atopic dermatitis, allergic rhinitis, hyperimmunoglobulinemia E and Kimura’s disease. The treatment with suplatast tosilate in steroid-dependent asthma improves pulmonary function and symptom control, and allows a decrease in dose of inhaled corticosteroid without significant side-effects. Studies show that suplatast tosilate capsules improve the airway inflammation and inhibit airway hyperresponsiveness (T. Horiguchi, S. Tachikawa et al. Effects of Suplatast Tosilate on Airway Inflammation and Airway Hyperresponsiveness // The Journal of Asthma, 2001, June, 38(4): 331-6). However, this medicine does not rapidly alleviate already occurring asthma attacks or symptoms.